ethyl 2-(4-oxo-thioxothiazolidin-3-yl)ethanesulfonate | 1146616-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: ethyl 2-(4-oxo-thioxothiazolidin-3-yl)ethanesulfonate
• 英文别名: Ethyl 2-(4-oxo-2-thioxothiazolidin-3-yl)-ethanesulfonate；ethyl 2-(4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl)ethanesulfonate
• CAS: 1146616-07-0
• 化学式: C₇H₁₁NO₄S₃
• 分子量: 269.367
• InChiKey: HGXBWNMKTDIBCI-UHFFFAOYSA-N

物化性质

• 沸点：
  444.1±47.0 °C(predicted)
• 密度：
  1.53±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  129
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  乙基香兰素 、 ethyl 2-(4-oxo-thioxothiazolidin-3-yl)ethanesulfonate 在 sodium acetate 、 溶剂黄146 作用下， 生成
  参考文献：
  名称：

  VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE

  摘要：

  本文披露了一种可用于治疗癌症的天花H1相关（VHR）蛋白酪氨酸磷酸酶（PTP）抑制剂。

  公开号：

  US20090105254A1
• 作为产物：
  描述：

  4-thioxo-3,5-dithia-heptanedioic acid dimethyl ester 、 2-aminoethanesulfonic acid ethyl ester 以 水 为溶剂， 生成 ethyl 2-(4-oxo-thioxothiazolidin-3-yl)ethanesulfonate
  参考文献：
  名称：

  VHR PROTEIN TYROSINE PHOSPHATASE INHIBITORS, COMPOSITIONS AND METHODS OF USE

  摘要：

  本文披露了一种可用于治疗癌症的天花H1相关（VHR）蛋白酪氨酸磷酸酶（PTP）抑制剂。

  公开号：

  US20090105254A1

文献信息

• Shp-2 inhibitors, pharmaceutical compositions comprising them and their use for treating phosphatase-mediated diseases
  申请人：MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN

  公开号：EP1728790A1

  公开（公告）日：2006-12-06

  The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).

  本发明涉及小分子蛋白酪氨酸磷酸酶抑制剂，特别是Shp-2抑制剂，其化学式为(I)或(II)，以及包含它们的制药组合物。本发明还涉及使用所述化合物治疗磷酸酶介导的疾病，特别是癌症和转移的用途。本发明进一步涉及一种用于治疗患有增殖性疾病、遗传性疾病、自身免疫性疾病、血管生成性疾病或癌症的患者的方法，包括向该患者施用至少一种化合物(I)和/或(II)的治疗有效量。
• Shp-2 Inhibitors, Pharmaceutical Compositons Comprising Them and Their Use For Treating Phosphatase-Mediated Diseases
  申请人：Hellmuth Klaus

  公开号：US20080194563A1

  公开（公告）日：2008-08-14

  The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).

  本发明涉及小分子蛋白酪氨酸磷酸酶抑制剂，特别是Shp-2抑制剂，其化学式为(I)和/或(II)，以及包含它们的制药组合物。该发明还涉及使用所述化合物治疗磷酸酶介导的疾病，特别是癌症和转移。本发明还涉及一种治疗增殖性疾病、遗传性疾病、自身免疫性疾病、血管生成障碍或癌症的方法，包括向该患者施用至少一种化合物(I)和/或(II)的治疗有效量。
• Shp-2 inhibitors and pharmaceutical compositions comprising them
  申请人：Max-Delbruck-Centrum fur Molekulare Medizin

  公开号：US07868185B2

  公开（公告）日：2011-01-11

  The present invention relates to small molecule protein tyrosine phosphatase inhibitors, especially Shp-2 inhibitors, of formula (I) and/or (II), and to pharmaceutical compositions comprising them. The invention is also directed to the use of said compounds for the treatment of phosphatase-mediated diseases, especially cancer and metastasis. The invention further concerns a method for treating a proliferative disease, a genetic disorder, an autoimmune disease, an angiogenic disorder or cancer in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of formula (I) and/or (II).

  本发明涉及小分子蛋白酪氨酸磷酸酶抑制剂，特别是Shp-2抑制剂，其化学式为(I)和/或(II)，以及包含它们的制药组合物。本发明还涉及使用所述化合物治疗磷酸酶介导的疾病，特别是癌症和转移。本发明还涉及一种治疗增殖性疾病、遗传性疾病、自身免疫疾病、血管生成异常或癌症的方法，包括向需要该治疗的患者施用至少一种化合物(I)和/或(II)的治疗有效量。
• SHP-2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE FOR TREATING PHOSPHATASE-MEDIATED DISEASES
  申请人：MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN

  公开号：EP1885717B1

  公开（公告）日：2011-08-17
• US7868185B2
  申请人：——

  公开号：US7868185B2

  公开（公告）日：2011-01-11